Sugi Predict

Sugi Predict / Compounds / SCHEMBL16047423

SCHEMBL16047423

SCHEMBL16047423

CCc1cc2cc(Cl)c(O)c(C(=O)O)c2o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 1/20 0.47
▸ SLC22A12 Q96S37 7/20 0.43
▸ DPP4 P27487 1/20 0.39
▸ TTR P02766 3/20 0.36
▸ PTGER1 P34995 1/20 0.34
▸ GPR35 Q9HC97 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ CASP1 P29466 2/20 0.33
▸ CASP7 P55210 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ AKR1C2 P52895 2/20 0.33
▸ AKR1C1 Q04828 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ AKR1C4 P17516 1/20 0.33
▸ AKR1C3 P42330 1/20 0.33
▸ FABP3 P05413 1/20 0.33
▸ FABP4 P15090 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16047639 0.85 SLC22A12 (0.43) STING1SLC22A12TTRHPGDHSD17B10
SCHEMBL16048063 0.73 SLC22A12 (0.39) SLC22A12HPGDPDE4APDE4BPDE4C
SCHEMBL16047815 0.73 SLC22A12 (0.39) SLC22A12HPGDCASP1HSD17B10POLB
SCHEMBL29784623 0.72 STING1 (0.38) STING1SLC22A12HPGDPOLBKDM4E
SCHEMBL16047262 0.72 SLC22A12 (0.41) SLC22A12HSD17B10PDE4APDE4BPDE4C
SCHEMBL27185616 0.72 STING1 (0.38) STING1SLC22A12HPGDPOLBKDM4E
SCHEMBL22416115 0.72 STING1 (0.46) STING1SLC22A12HPGDHSD17B10ALOX15
SCHEMBL27185844 0.71 STING1 (0.48) STING1DPP4HPGDPOLB
SCHEMBL2806039 0.71 SLC22A12 (0.46) SLC22A12DPP4HPGDHSD17B10POLB
SCHEMBL16046498 0.70 SLC22A12 (0.37) SLC22A12HPGDHSD17B10POLBPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254647-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV (BE) 2022-02-22 — — US disclosed
EP-3421458-B1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2020-11-11 — — EP disclosed
US-20200317629-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2020-10-08 — — US disclosed
US-10730847-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV (BE) 2020-08-04 — — US disclosed
US-20190152937-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2019-05-23 — — US disclosed
EP-3421458-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 Janssen Pharmaceutica NV (BE) 2019-01-02 — — EP disclosed
US-10155737-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV (BE) 2018-12-18 — — US disclosed
EP-2970157-B1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2018-04-25 — — EP disclosed
US-20170088531-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2017-03-30 — — US disclosed
US-9562053-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV (BE) 2017-02-07 — — US disclosed
EP-2970157-A2 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP disclosed
WO-2014159061-A2 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2014-10-02 — — WO disclosed
US-20140275172-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155737-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885
US-20200317629-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885
US-20190152937-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885
US-20140275172-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885
US-20170088531-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885
US-11254647-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885
US-10730847-B2 Benzo-fused heterocyclic derivatives useful as agonists of GPR120 GPR119, GPR180, GPR55 STING1 1777/4885SLC22A12 1221/4885DPP4 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.